Tezepelumab Efficacy in Patients with Severe, Uncontrolled Asthma with Comorbid Nasal Polyps in NAVIGATOR [Corrigendum]

Abstract

Laidlaw TM, Menzies-Gow A, Caveney S, et al. J Asthma Allergy. 2023;16:915–932. The authors have advised there is an error in Figure 1 on page 922. The n= x-axis data were transposed for the treatment groups for both the Patients with NPs and Patients without NPs. The correct Figure 1 is as follows. Figure 1 AAER over 52 weeks in patients with or without nasal polyps in the 2 years before randomization in the NAVIGATOR study.Abbreviations: AAER, annualized asthma exacerbation rate; CI, confidence interval; NP, nasal polyp; Q4W, every 4 weeks.Note: n, number of patients contributing to the analysis. The authors apologize for this error.

Keywords

• chronic rhinosinusitis
• nasal polyps
• snot-22
• thymic stromal lymphopoietin